{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:08Z","timestamp":1792698128316,"version":"4.5.0"},"reference-count":77,"publisher":"Georg Thieme Verlag KG","issue":"03","funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"crossref","award":["R37 AA020703, U01 AA026939, U01 AA026939-04S1,P50 AA011999,R01 AA24726"],"award-info":[{"award-number":["R37 AA020703, U01 AA026939, U01 AA026939-04S1,P50 AA011999,R01 AA24726"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["P30 DK120515"],"award-info":[{"award-number":["P30 DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Globally, liver disease caused by alcohol is becoming more prevalent each year. Misuse of alcohol causes a spectrum of liver diseases, such as liver steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The cornerstone of treatment is abstinence from alcohol. In spite of this, available treatment for alcohol-associated liver disease (ALD) shows limited effectiveness currently. There are numerous ways in which alcohol disrupts the gut\u2013liver axis, including dysbiosis of the gut microbiome, disruption of mucus and epithelial cell barriers, impaired production of antimicrobial molecules, and dysfunction of the immune system, causing translocation of viable microbes and microbial products to the liver and systemic circulation. Microbial exposure results in not only inflammation and progression of liver disease but also infections in late-stage ALD. This led scientists to focus their therapeutic strategies and targets for ALD on the gut microbiome. Throughout this review, we address the role of gut microbiome\u2013centered therapeutic approaches for ALD focusing predominantly on randomized controlled trials. We will summarize the latest clinical trials using probiotics, antibiotics, and fecal microbial transplants in modulating the gut\u2013liver axis and for improvement of ALD.<\/jats:p>","DOI":"10.1055\/a-2145-7331","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T23:04:41Z","timestamp":1690931081000},"page":"311-322","source":"Crossref","is-referenced-by-count":16,"title":["Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease"],"prefix":"10.1055","volume":"43","author":[{"given":"Tannaz","family":"Ranjbarian","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schnabl","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, La Jolla, California"},{"name":"Department of Medicine, VA San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamainternmed.2018.6536","article-title":"National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States","volume":"179","author":"B P Lee","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","article-title":"Global burden of alcoholic liver diseases","volume":"59","author":"J Rehm","year":"2013","journal-title":"J Hepatol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/acer.12331","article-title":"Burden of disease associated with alcohol use disorders in the United States","volume":"38","author":"J Rehm","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/nrdp.2016.41","article-title":"Acute-on-chronic liver failure in cirrhosis","volume":"2","author":"V Arroyo","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1056\/NEJMra1715733","article-title":"Alcohol use in patients with chronic liver disease","volume":"379","author":"D Fuster","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"R Bataller","year":"2022","journal-title":"N Engl J Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo - a meta-analysis of individual data from controlled trials","volume":"155","author":"A Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cld.2012.08.002","article-title":"Alcohol metabolism","volume":"16","author":"A I Cederbaum","year":"2012","journal-title":"Clin Liver Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"9370565","DOI":"10.1155\/2016\/9370565","article-title":"Behavior of oxidative stress markers in alcoholic liver cirrhosis patients","author":"M Galicia-Moreno","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","article-title":"Oxidative stress","volume":"86","author":"H Sies","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12688\/f1000research.14841.1","article-title":"Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts","volume":"7","author":"R Weiskirchen","year":"2018","journal-title":"F1000 Res"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/hepr.12736","article-title":"Pathogenesis of alcoholic liver disease","volume":"47","author":"K Sugimoto","year":"2017","journal-title":"Hepatol Res"},{"issue":"7402","key":"ref13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome","volume":"486","author":"H MP Consortium","year":"2012","journal-title":"Nature"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00431-014-2476-2","article-title":"The intestinal microbiota: its role in health and disease","volume":"174","author":"L Biedermann","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"03","key":"ref15","first-page":"6","article-title":"Gut\u2013liver axis: How do gut bacteria influence the liver?","volume":"6","author":"P C Konturek","year":"2018","journal-title":"Med Sci (Basel)"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/hep4.1537","article-title":"Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis","volume":"4","author":"B Gao","year":"2020","journal-title":"Hepatol Commun"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2016.01.003","article-title":"Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation","volume":"19","author":"L Wang","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"01","key":"ref18","first-page":"30","article-title":"Jejunal microflora in patients with chronic alcohol abuse","volume":"31","author":"J C Bode","year":"1984","journal-title":"Hepatogastroenterology"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/j.1572-0241.2002.05791.x","article-title":"Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia","volume":"97","author":"T M Bauer","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"7783","key":"ref20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Y Duan","year":"2019","journal-title":"Nature"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30832","article-title":"Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis","volume":"71","author":"S Lang","year":"2020","journal-title":"Hepatology"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","article-title":"Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease","volume":"67","author":"C Grander","year":"2018","journal-title":"Gut"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"J S Bajaj","year":"2014","journal-title":"J Hepatol"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","article-title":"The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease","volume":"72","author":"H Chu","year":"2020","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","author":"C L Hsu","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1785251","DOI":"10.1080\/19490976.2020.1785251","article-title":"Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients","volume":"12","author":"S Lang","year":"2020","journal-title":"Gut Microbes"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0036-1593882","article-title":"Bidirectional communication between liver and gut during alcoholic liver disease","volume":"36","author":"P St\u00e4rkel","year":"2016","journal-title":"Semin Liver Dis"},{"key":"ref28","first-page":"6","article-title":"The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer","volume":"6","author":"N M\u00e9ndez-S\u00e1nchez","year":"2020","journal-title":"Hepatoma Res"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1586\/17474124.2015.1057122","article-title":"Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?","volume":"9","author":"K Brandl","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"08","key":"ref30","first-page":"1509","article-title":"Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice","volume":"35","author":"S Inokuchi","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"E Seki","year":"2007","journal-title":"Nat Med"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1038\/s41467-021-27385-3","article-title":"CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease","volume":"12","author":"Y Duan","year":"2021","journal-title":"Nat Commun"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.27921","article-title":"Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1","volume":"62","author":"B Chang","year":"2015","journal-title":"Hepatology"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/acer.15048","article-title":"Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice","volume":"47","author":"T Kouno","year":"2023","journal-title":"Alcohol (Hanover)"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"M Llopis","year":"2016","journal-title":"Gut"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2008.10.080","article-title":"Microbes in gastrointestinal health and disease","volume":"136","author":"A S Neish","year":"2009","journal-title":"Gastroenterology"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3892\/etm.2021.9619","article-title":"Lactobacillus spp. reduces ethanol-induced liver oxidative stress and inflammation in a mouse model of alcoholic steatohepatitis","volume":"21","author":"P S Hsieh","year":"2021","journal-title":"Exp Ther Med"},{"issue":"24","key":"ref38","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3748\/wjg.v17.i24.2890","article-title":"Probiotics in hepatology","volume":"17","author":"J Lata","year":"2011","journal-title":"World J Gastroenterol"},{"key":"ref39","first-page":"9097276","article-title":"Probiotics for alleviating alcoholic liver injury","author":"Z Gu","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"08","key":"ref40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/s41430-020-00852-8","article-title":"Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury","volume":"75","author":"X Li","year":"2021","journal-title":"Eur J Clin Nutr"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study","volume":"42","author":"I A Kirpich","year":"2008","journal-title":"Alcohol"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/MEG.0000000000000458","article-title":"Effects of probiotics (cultured Lactobacillus subtilis\/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study","volume":"27","author":"S H Han","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"08","key":"ref43","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.14309\/ajg.0000000000002283","article-title":"The beneficial effects of Lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis","volume":"118","author":"V Vatsalya","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"R Wiest","year":"2014","journal-title":"J Hepatol"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis","volume":"41","author":"R Wiest","year":"2005","journal-title":"Hepatology"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jhep.2008.02.015","article-title":"Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis","volume":"48","author":"V Stadlbauer","year":"2008","journal-title":"J Hepatol"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/nu12061651","article-title":"A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei Shirota in stable cirrhotic patients","volume":"12","author":"J Macnaughtan","year":"2020","journal-title":"Nutrients"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.20126","article-title":"Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial","volume":"39","author":"M C Hou","year":"2004","journal-title":"Hepatology"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","article-title":"Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study","volume":"55","author":"J Fern\u00e1ndez","year":"2012","journal-title":"Hepatology"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"N M Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jgh.13852","article-title":"Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: a randomized trial","volume":"33","author":"N Kimer","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"J S Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/ctg.2016.44","article-title":"Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition","volume":"7","author":"D J Kang","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"C Jim\u00e9nez","year":"2022","journal-title":"Liver Int"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"e0264278","DOI":"10.1371\/journal.pone.0264278","article-title":"The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial","volume":"17","author":"N Kimer","year":"2022","journal-title":"PLoS One"},{"issue":"18","key":"ref56","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial","volume":"329","author":"A Louvet","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2018.09.013","article-title":"Alcohol-associated cirrhosis","volume":"23","author":"M R Lucey","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cgh.2022.05.042","article-title":"Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials","volume":"21","author":"J S Bajaj","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"J Vlachogiannakos","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"07","key":"ref60","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"G N Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1478-3231.2011.02650.x","article-title":"Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia","volume":"32","author":"G N Kalambokis","year":"2012","journal-title":"Liver Int"},{"issue":"24","key":"ref62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/jci.insight.133410","article-title":"Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis","volume":"4","author":"J S Bajaj","year":"2019","journal-title":"JCI Insight"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2018.10.019","article-title":"Microbiome as a therapeutic target in alcohol-related liver disease","volume":"70","author":"S K Sarin","year":"2019","journal-title":"J Hepatol"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"A Sharma","year":"2022","journal-title":"Hepatol Int"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"C A Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"C A Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"C A Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial","volume":"17","author":"A Pande","year":"2023","journal-title":"Hepatol Int"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial","volume":"70","author":"J S Bajaj","year":"2019","journal-title":"Hepatology"},{"issue":"06","key":"ref70","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"J S Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hep4.1639","article-title":"Fecal microbiota transplant in cirrhosis reduces gut microbial antibiotic resistance genes: analysis of two trials","volume":"5","author":"J S Bajaj","year":"2020","journal-title":"Hepatol Commun"},{"issue":"42","key":"ref72","doi-asserted-by":"crossref","first-page":"E4485","DOI":"10.1073\/pnas.1415174111","article-title":"Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity","volume":"111","author":"S Leclercq","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"05","key":"ref73","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"J S Bajaj","year":"2021","journal-title":"Hepatology"},{"issue":"21","key":"ref74","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"Z DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"e0119362","DOI":"10.1371\/journal.pone.0119362","article-title":"Alcohol induced alterations to the human fecal VOC metabolome","volume":"10","author":"R D Couch","year":"2015","journal-title":"PLoS One"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","article-title":"Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice","volume":"68","author":"T Hendrikx","year":"2019","journal-title":"Gut"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/hep4.1322","article-title":"Serum metabolomic profiling identifies key metabolic signatures associated with pathogenesis of alcoholic liver disease in humans","volume":"3","author":"Z Yang","year":"2019","journal-title":"Hepatol Commun"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2145-7331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T14:16:40Z","timestamp":1729865800000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2145-7331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":77,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2145-7331","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,8]]}}}